Alpha 2.0
Login Register
» Authors » Hans-Gerd Meerpohl

Hans-Gerd Meerpohl

Explore the profile of Hans-Gerd Meerpohl including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 242
Followers 0
Related Specialty
Oncology
Top 10 Co-Authors
Jalid Sehouli
Nadia Harbeck
Philipp Harter
Harald Sommer
Andreas du Bois
Wolfgang Abenhardt
Almut Artmann
Gerhard Rauthe
Ursula Vehling Kaiser
Hans-Joachim Stemmler
Published In
Oncology
Ann Surg Oncol
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
Tian W, Chi D, Sehouli J, Trope C, Jiang R, Ayhan A, et al.
Ann Surg Oncol . 2011 Jul; 19(2):597-604. PMID: 21732142
Background: To develop a risk model for predicting complete secondary cytoreductive surgery (SCR) in patients with recurrent ovarian cancer. Methods: Individual data of 1075 patients with recurrent ovarian cancer undergoing...
2.
Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer
Stemmler H, Harbeck N, Groll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, et al.
Oncology . 2011 Mar; 79(3-4):204-10. PMID: 21358208
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to compare the toxicity and efficacy of...
3.
Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer
Stemmler H, Harbeck N, Groll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, et al.
Oncology . 2011 Mar; 79(3-4):197-203. PMID: 21358207
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to randomly compare the toxicity and efficacy...
4.
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al.
J Clin Oncol . 2010 Dec; 29(2):242-8. PMID: 21115872
Purpose: Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted...
5.
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin...
Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl H, Lichinitser M, et al.
J Clin Oncol . 2010 Feb; 28(9):1473-80. PMID: 20177030
Purpose: A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES)...
6.
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al.
Ann Surg Oncol . 2006 Sep; 13(12):1702-10. PMID: 17009163
Background: The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection...
7.
Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer
Al-Batran S, Meerpohl H, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, et al.
Oncology . 2006 Apr; 70(2):141-6. PMID: 16645327
Purpose: The aim of this study was to assess whether the reduction in the total dose of pegylated liposomal doxorubicin (PLD) per cycle from 50 mg/m(2) every 4 weeks to...